Nika Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Nika Pharmaceuticals' latest 10-K filing reveals significant financial distress, including a going concern warning and ineffective internal controls, despite a reduced net loss.
OQB
Nika Pharmaceuticals' 2024 Form 10-K reveals a net loss increase to $95,792, alongside strategic shifts including a common control merger and OTCQB uplisting.
OQB
10-K: Nika Pharmaceuticals Reports Full Year 2023 Results, Focuses on Growth and Strategic Partnerships
Nika Pharmaceuticals reported a net loss of $64,833 for 2023, a significant decrease from the $3,183,715 loss in 2022, as the company transitions its business focus towards pharmaceutical and dietary supplement development.